Madrigal Pharmaceuticals Secures $500MM from Blue Owl Managed Funds
Madrigal Pharmaceuticals, a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), entered into a $500 million senior secured credit facility with funds managed by Blue Owl Capital, an alternative asset manager, to primarily advance Madrigal’s pipeline...
Read moreDetails








